doi: 10.1016/j.crohns.2014.06.013 80 ChambersESNanzerAMPfefferPERichardsDFTimmsPMMartineauARet al
*Correspondence: Bin Cong, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Depression and mood changes, though not commonly reported with GLP-1 receptor agonists, should be considered in the differential diagnosis of fatigue
Participants were trained to self-inject and received periodic retraining during the trial
Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma
H., Manczak, M., & Kandimalla, R